The Readout Loud
327: Biotech's next gold rush, GLP-1 shortages, and STAT Summit highlights
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Elaine, Allison, and Adam chat about investors' interest in using CAR-T to treat autoimmune conditions, the latest developments with the supply of Eli Lilly’s blockbuster weight loss drug, and the invisible medical groups behind the dozens of telehealth platforms providing GLP-1 drugs. They also look back at STAT's two-day summit that brought together biopharma executives, scientists, policymakers and patient advocates for conversations about the future of health care.